Will Advisory Committee Review Vindicate Pfizer’s Vyndaqel?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s orphan drug tafamidis will be reviewed by FDA’s Peripheral and Central Nervous System Drugs Advisory Committee in May. The scheduling of a panel during a priority review is some indication FDA has concern, but the panels of outside experts are generally receptive to rare disease treatments.